CAR T-cell Therapy

Noelle Frey, MD, discusses the FDA approvals of CAR T-cell therapies, as well as the bright future of the treatment.

Bijal D. Shah, MD, medical oncology, Moffit Cancer Center, discusses the importance of chimeric antigen receptor (CAR) T-cell therapy for patients with acute lymphoblastic leukemia (ALL).

The FDA has granted the the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma.

Sarah K. Tasian, MD, discusses the success of CAR T-cell therapy, as well as novel agents and immunotherapies that appear promising in the treatment of children with leukemia.

Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).

Leo I. Gordon, MD, discusses promising advances and lingering challenges with novel treatments for patients with hematologic malignancies.

The high rates of cerebral edema seen with JCAR015 in the phase II ROCKET trial were attributed to early and rapid chimeric antigen receptor (CAR)-modified T-cell expansion and a rise in interleukin-15 levels, a finding that could help inform future CAR T-cell usage.

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.

A variety of adoptive T-cell therapy strategies have shown promise in clinical studies with recent FDA approvals granted to CAR-modified T-cell therapies, representing the potential for future combination strategies.

The FDA today lifted clinical holds placed on 2 phase I trials investigating a gene-edited allogeneic CAR T-cell therapy known as UCART123.

The European Medicines Agency (EMA) has received a Marketing Authorization Application (MAA) for tisagenlecleucel (Kymriah) for 2 forms of advanced lymphoma.

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the future treatment landscape for chimeric antigen receptor (CAR) T-cell therapy.

Edward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.

David G. Maloney, MD, PhD, discusses the progress made with CAR T cells, as well as the challenges that still exist in the use of this therapy.

Novartis has filed a supplemental biologics license application with the FDA to expand the indication for tisagenlecleucel (Kymriah) to include adults with relapsed/refractory DLBCL who are ineligible for ASCT.

Reem Karmali, MD, discusses ongoing key trials of CAR T-cell therapy, the chronic safety concerns with the treatment, and what combinations have the most potential.

Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the future of chimeric antigen receptor (CAR) T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Leo I. Gordon, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the concerns of chimeric antigen receptor (CAR) T-cell therapy.

Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the toxicities associated with the use of chimeric antigen receptor (CAR) T-cell therapies.

Andre Goy, MD, discusses the recent success with CAR T-cell therapy, and what is on the horizon for this therapeutic option across hematologic malignancies.

The FDA has approved the CD19-directed CAR T-cell therapy axicabtagene ciloleucel as a treatment for adults with relapsed or refractory non-Hodgkin lymphoma.

Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the FDA approval of axicabtagene ciloleucel (KTE-C19; axi-cel) for the treatment of patients with non-Hodgkin lymphoma.